NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer.
Publication
, Preprint
Mehraj, U; Maimekov, U; Manzoor, S; Cordova, E; Patel, M; Mancera-Ortiz, IY; Howell, S; Davis-Gilbert, ZW; Wang, M-E; Chen, M; Park, JW ...
November 13, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Mehraj, U., Maimekov, U., Manzoor, S., Cordova, E., Patel, M., Mancera-Ortiz, I. Y., … Macias, E. (2025). NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer. https://doi.org/10.1101/2025.11.12.687734
Mehraj, Umar, Uran Maimekov, Shaista Manzoor, Emily Cordova, Manasiben Patel, Ikeer Y. Mancera-Ortiz, Stefanie Howell, et al. “NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer.,” November 13, 2025. https://doi.org/10.1101/2025.11.12.687734.
Mehraj U, Maimekov U, Manzoor S, Cordova E, Patel M, Mancera-Ortiz IY, et al. NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer. 2025.
Mehraj, Umar, et al. NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer. 13 Nov. 2025. Pubmed, doi:10.1101/2025.11.12.687734.
Mehraj U, Maimekov U, Manzoor S, Cordova E, Patel M, Mancera-Ortiz IY, Howell S, Davis-Gilbert ZW, Wang M-E, Chen M, Park JW, Wang Y, Armstrong AJ, Huang J, Drewry DH, Mitrofanova A, Macias E. NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer. 2025.